ImmunoVaccine Inc (CVE:IMV), a clinical stage vaccine and immunotherapy company, has been awarded a sub-contract by Leidos, a health, national security, and infrastructure solutions company.
The contract is to evaluate ImmunoVaccine's DepoVax platform for the development of peptide based malaria vaccine targets.
Leidos and ImmunoVaccine will work together to identify adjuvant and antigen combinations that can be used to protect against malaria and, with the DepoVax delivery system, formulate promising vaccine candidates for potential clinical testing.
"The flexibility and rapid immune response of Immunovaccine's DepoVax platform allows us to broaden application beyond immuno-oncology and collaborate with Leidos and other companies that are developing vaccines against diseases that cause widespread public health issues," said Frederic Ors, chief executive officer of ImmunoVaccine.
Ream more: http://www.proactiveinvestors.com/companies/news/127443/immunovaccine-inc-awarded-a-contract-for-malaria-vaccine-evaluation-127443.html